Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hiatt, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hiatt, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Risk factor modification in intermittent claudication: effect on life expectancy and walking capacity

W. Hiatt*

Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, U.S.A.

* Correspondence: William R. Hiatt, MD, Novartis Professor of Cardiovascular Research, University of Colorado Health Sciences Center, Colorado Prevention Center, 789 Sherman St., Suite 200, Denver, CO 80203, U.S.A.

Abstract

Peripheral arterial disease (PAD) is among the common manifestations of systemic atherosclerosis. In the U.S.A. it is estimated that this disorder affects 8–10 million adults, with resultant increased risk for cardiovascular morbidity and mortality. Thus, 50% of patients with PAD will have a fatal or non-fatal cardiovascular event within 5 years. The initial treatment goal in patients with PAD is to identify their risk factors for atherosclerosis and then to initiate risk factor modification. These patients should all be placed on antiplatelet therapy as well. However, these interventions typically do not result in an immediate change in the symptoms of PAD, mainly intermittent claudication, and additional interventions are necessary to treat this disabling symptom. These include a formal exercise programme; with regard to pharmacological therapies cilostizol is available in the U.S.A., and several medications that are effective including propionyl-L- carnitine are available in Europe.

Key Words: Intermittent claudication • peripheral arterial disease

References

  1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–1621[Free Full Text]
  2. Hiatt WR, Hoag S, Hamman RE. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. Circulation. : The San Luis Valley diabetes study; 1995. p. 1472–1479
  3. Beach KW, Strandness DE. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non-insulindependent diabetes. Diabetes. 1980;29:882–888[Abstract]
  4. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894–903 Anonymous[CrossRef][Web of Science][Medline]
  5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. : UK Prospective Diabetes Study (UKPDS) Group; 1998. p. 837–853 Anonymous
  6. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med. 1998;338:645–652[Abstract/Free Full Text]
  7. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Mod. 1999;131:281–303
  8. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WE. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96:44–49[Abstract/Free Full Text]
  9. Quick CRG, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982;69:S24–S26 (suppl)
  10. Stewart CP. The influence of smoking on the level of lower limb amputation. Prosthet Orthot Int. 1987;11:113–116[Web of Science][Medline]
  11. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Acta Med Scand. 1987;221:253–260[Web of Science][Medline]
  12. Girolami B, Bernardi F, Prins MH, et al. Treatment of intermittent claudication with physical training smoking cassation, pentoxfylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159:337–345[Abstract/Free Full Text]
  13. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000;284:1263–1270[Abstract/Free Full Text]
  14. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis (Cochrane Review). The Cochrane Library. Oxford: Update Software; 1999.
  15. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81:333–335[CrossRef][Web of Science][Medline]
  16. Kahn F, Litchfield SJ, Belch JJ. Cutaneous microvascular responses are improved after cholesterol-lowering in patients with peripheral arterial disease. Adv Exp Med Biol. 1997;428:49–54[Web of Science][Medline]
  17. AnonymousJAMA. 2001. p. 2486–2497
  18. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of NCEP Adult Treatment Panel 11 guidelines. National Cholesterol Education Program. JAMA. 1999;282:2051–2057[Abstract/Free Full Text]
  19. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Mod. 1997;157:2413–2446 Anonymous
  20. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Mod. 1991;151:1769–1776
  21. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. N Engl J Med. 1999;341:1789–1794[Abstract/Free Full Text]
  22. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153[Abstract/Free Full Text]
  23. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. : Antiplatelet Trialists' Collaboration; 1994. p. 81–106 Anonymous
  24. Collaborative overview of randomised trials of antiplatelet therapy. II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. : Antiplatelet Trialists' Collaboration; 1994. p. 159–168 Anonymous
  25. Goldhabez SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent arterial surgery in the Physician Health Study. Lancet. 1992;340:143–145[CrossRef][Web of Science][Medline]
  26. Berqvist D, Almgren B, Dickinson JP. Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). Eur J Vasc Endovasc Surg. 1995;10:69–76[CrossRef][Web of Science][Medline]
  27. Bokissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost. 1996;62:681–685
  28. Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology. 1988;39:802–811
  29. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339[CrossRef][Web of Science][Medline]
  30. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995;274:975–980[Abstract/Free Full Text]
  31. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996;23:104–115[CrossRef][Web of Science][Medline]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hiatt, W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hiatt, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?